TABLE 1.
Range of anti-HIV activity of SJ-3366 in established human cell lines
| Virus (isolate) | CELLb | IC50
(μM)a
|
||
|---|---|---|---|---|
| SJ-3366 | Nevirapine | AZT | ||
| HIV-1 (IIIB) | CEM-SS | 0.0009 | 0.1 | 0.003 |
| HIV-1 (RF) | CEM-SS | 0.001 | 0.2 | 0.004 |
| HIV-1 (SK1) | CEM-SS | 0.002 | 0.2 | 0.005 |
| HIV-1 (IIIB) | 174×CEM | 0.003 | 0.1 | 0.03 |
| HIV-1 (IIIB) | MT2 | 0.001 | 0.1 | 0.04 |
| HIV-1 (IIIB) | U937 | 0.01 | 0.3 | 0.003 |
| HIV-1 (IIIB) | AA5 | 0.009 | 0.7 | 0.01 |
| HIV-2 (ROD) | CEM-SS | 0.17 | >38 | 0.005 |
| SIV (DeltaB670) | 174×CEM | >100 | >38 | 0.02 |
a
The results presented were obtained from a single representative antiviral assay, with appropriate nevirapine and AZT control values selected from a minimum of two antiviral assays. We have demonstrated that the standard error between multiple antiviral assays averaged less than 10% of the respective mean IC50.
b
Cellular phenotypes: CEM-SS, T cell; 174×CEM, T-cell–B-cell fusion; U937, macrophage; AA5, Epstein-Barr virus-infected B-cell.